Skip to main content

Table 2 Surgical indications in 110 pancreaticoduodenectomies

From: Comparison of clinical outcomes between mesh-reinforced pancreatojejunostomy and pancreatogastrostomy following pancreaticoduodenectomy: a cohort study

 

All (n = 110)

PG group (n = 51)

PJ group (n = 59)

P value

Ampullary carcinoma*

35 (31.8)

17 (33.3)

18 (30.5)

0.75

Distal biliary cancer*

16 (14.5)

7 (13.7)

9 (15.3)

0.82

Duodenal cancer*

16 (14.5)

7 (13.7)

9 (15.3)

0.82

Ductal cancer*

15 (13.6)

7 (13.7)

8 (13.6)

0.98

Cystic tumors*

9 (8.2)

4 (7.8)

5 (8.5)

0.90

Endocrine tumors*

5 (4.5)

3 (5.9)

2 (3.4)

0.53

Intraductal papillary mucinous tumor*

5 (4.5)

2 (3.9)

3 (5.1)

0.77

Other indications*

9 (8.2)

4 (7.8)

5 (8.5)

0.90

  1. PG pancreatogastrostomy, PJ pancreatojejunostomy
  2. *Values are expressed as n (%)